Daniels Joshua B, Call Douglas R, Hancock Dale, Sischo William M, Baker Katherine, Besser Thomas E
Department of Veterinary Microbiology and Pathology, Washington State University College of Veterinary Medicine, Pullman, WA 99164, USA.
Appl Environ Microbiol. 2009 Jun;75(11):3648-55. doi: 10.1128/AEM.02435-08. Epub 2009 Apr 17.
Third-generation cephalosporin resistance of Salmonella and commensal Escherichia coli isolates from cattle in the United States is predominantly conferred by the cephamycinase CMY-2, which inactivates beta-lactam antimicrobial drugs used to treat a wide variety of infections, including pediatric salmonellosis. The emergence and dissemination of bla(CMY-2)(-)-bearing plasmids followed and may in part be the result of selection pressure imposed by the widespread utilization of ceftiofur, a third-generation veterinary cephalosporin. This study assessed the potential effects of ceftiofur on bla(CMY-2) transfer and dissemination by (i) an in vivo experimental study in which calves were inoculated with competent bla(CMY-2)-bearing plasmid donors and susceptible recipients and then subjected to ceftiofur selection and (ii) an observational study to determine whether ceftiofur use in dairy herds is associated with the occurrence and frequency of cephalosporin resistance in Salmonella and commensal E. coli. The first study revealed bla(CMY-2) plasmid transfer in both ceftiofur-treated and untreated calves but detected no enhancement of plasmid transfer associated with ceftiofur treatment. The second study detected no association (P = 0.22) between ceftiofur use and either the occurrence of ceftiofur-resistant salmonellosis or the frequency of cephalosporin resistance in commensal E. coli. However, herds with a history of salmonellosis (including both ceftiofur-resistant and ceftiofur-susceptible Salmonella isolates) used more ceftiofur than herds with no history of salmonellosis (P = 0.03) These findings fail to support a major role for ceftiofur use in the maintenance and dissemination of bla(CMY-2)-bearing plasmid mediated cephalosporin resistance in commensal E. coli and in pathogenic Salmonella in these dairy cattle populations.
美国牛群中分离出的沙门氏菌和共生大肠杆菌对第三代头孢菌素的耐药性主要由头孢菌素酶CMY-2介导,该酶可使用于治疗包括小儿沙门氏菌病在内的多种感染的β-内酰胺类抗菌药物失活。携带bla(CMY-2)质粒的出现和传播紧随其后,并且可能部分是由于第三代兽用头孢菌素头孢噻呋的广泛使用所施加的选择压力导致的。本研究通过以下方式评估了头孢噻呋对bla(CMY-2)转移和传播的潜在影响:(i)一项体内实验研究,给小牛接种携带bla(CMY-2)的质粒供体菌和敏感受体菌,然后进行头孢噻呋选择;(ii)一项观察性研究,以确定奶牛场中使用头孢噻呋是否与沙门氏菌和共生大肠杆菌中头孢菌素耐药性的发生和频率相关。第一项研究显示,在接受头孢噻呋治疗和未接受治疗的小牛中均发生了bla(CMY-2)质粒转移,但未检测到与头孢噻呋治疗相关的质粒转移增强。第二项研究未检测到头孢噻呋使用与头孢噻呋耐药性沙门氏菌病的发生或共生大肠杆菌中头孢菌素耐药性频率之间存在关联(P = 0.22)。然而,有沙门氏菌病史的牛群(包括对头孢噻呋耐药和敏感的沙门氏菌分离株)比没有沙门氏菌病史的牛群使用了更多的头孢噻呋(P = 0.03)。这些发现不支持头孢噻呋的使用在维持和传播共生大肠杆菌和这些奶牛种群中致病性沙门氏菌携带bla(CMY-2)质粒介导的头孢菌素耐药性方面起主要作用。